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Abstract
Introduction: Verigene® is one of many commercially available rapid diagnostic tests (RDT) for
organism identification in blood culture. Community Health Network (CHNw) utilizes this
system to identify blood cultures and guide antimicrobial therapy. As antibiotic resistance
becomes more and more prevalent, limiting exposure to broad-spectrum antibiotic therapy is of
paramount importance. RDT provides more timely information to providers, which if utilized
appropriately, can result in the patient receiving appropriate antibiotic therapy in a shorter time
and further limits unnecessary antibiotic exposure. CHNw evaluated the use of Verigene®
beginning in 2017 which led to the initiation of provider and pharmacist education of proper
Verigene® utilization.
Objectives: The primary objective of Aim 1 was to determine the accuracy of the Verigene® test
by comparing its results to the identified organism’s phenotypic susceptibility pattern. The
primary objective of Aim 2 was to re-evaluate the use of Verigene® within CHNw. Secondary
objectives were to compare all cause hospital mortality, 30-day readmission, hospital length of
stay (LOS), and duration of inpatient antibiotics. The primary objective of Aim 3 was to compare
Verigene® utilization across CHNw sites and to evaluate the impact of provider and pharmacist
education compared to pharmacist education alone.
Methods: In this three-part, retrospective chart review, demographic and clinical information was
collected from the electronic health record. Aim 1 data included clinical information such as
Verigene® organism, Verigene® resistance genes, phenotypic organism and susceptibility data
for target antimicrobials. Aim 2 and 3 data included demographic and clinical information such
as antibiotic therapy, time of de-escalation, duration of inpatient antibiotics, and positive culture
data. Patients 18-89 years of age with a positive, monomicrobic blood culture from July 1, 2015
to December 31, 2018 were included for Aim 1 and those with a positive blood culture for
Escherichia coli from July 1, 2018 to December 31, 2018 were included for Aims 2 and 3.
Results: Aim 1 analyzed 2,052 isolates: 637 Staphylococcus aureus, 22 Enterococcus spp., 739
Escherichia coli, and 654 Klebsiella pneumoniae. Ceftriaxone resistance was present in 101
(13.7%) of E. coli and K. pneumoniae (excluding KPC genes) isolates and 81 (80.2%) of these
were identified with the CTX-M resistance marker by Verigene®. Meropenem resistance was
present in 8 (1.2%) of K. pneumoniae isolates and 3 (37.5%) of those were identified with KPC.
Oxacillin resistance was present in 255 (40.0%) of S. aureus isolates and 254 (99.6%) of those
were identified with MecA. Vancomycin resistance was present in 22 (100%) of Enterococcus
spp. isolates and all were identified with VanA or VanB. Aim 2 showed Verigene® was utilized
to de-escalate antimicrobials prior to phenotypic susceptibilities in 29 of 85 patients (34.1%).
There was no statistically significant difference in all-cause mortality between the Verigene®
utilized group and Verigene® not utilized group (5/29 (17.2%) vs. 7/56 (12.5%), p = 0.533). The
mean duration of inpatient antibiotics did not vary significantly between groups (5.69 days SD
±2.055 in Verigene® utilized group vs. 6.25 days ±2.881 in Verigene® not utilized, p=0.305).
Aim 3 results pending.
Discussion: The results of this study show that providers should have increased confidence in the
utilization and accuracy of Verigene®; however, in the case of E. coli bacteremia, Verigene® is
still not being utilized to de-escalate therapy despite educational efforts. More robust education
or additional methods/resources are needed to improve the utility of Verigene® within CHNw.
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Introduction
Verigene® is one of many commercially available rapid diagnostic tests (RDT) for
organism identification in blood culture. Verigene® tests utilize NanoGrid technology to detect
DNA or RNA targets using nucleic acid extraction and PCR amplification. The nucleic acids are
automatically transferred to a Verigene® test cartridge for primary and secondary hybridization
where oligonucleotides are captured on a microarray and amplified for automated qualitative
analysis.1 The Verigene® blood culture gram-positive (BC-GP) assay can identify unique
Staphylococcus, Streptococcus, Enterococcus, and Listeria species including the resistance
markers MecA (denotes methicillin-resistant S. aureus (MRSA)), and VanA and VanB (denotes
vancomycin resistance in Enterococci). The Verigene® blood culture gram-negative (BC-GN)
assay can identify Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas
aeruginosa, Acinetobacter species, Proteus species, Citrobacter species and Enterobacter species
including the resistance markers for Klebsiella producing carbapenemase (KPC), New Delhi
metallo-beta-lactamase (NDM), Cefotaxime hydrolyzing enzyme (CTX-M), Verona integrinencoded metallo-beta-lactamase (VIM), Imipenem hydrolyzing enzyme (IMP) and Oxacillin
hydrolyzing enzymes (OXA) genes. These genes target commonly encountered and/or clinically
challenging beta-lactamases that can readily hydrolyze a wide variety of beta-lactam antibiotics,
including carbapenems, piperacillin-tazobactam, and cefepime, respectively.2, 3
Laboratory testing using traditional methods such as Gram staining and culture-based
techniques require 24-72 hours for results to return before optimal antimicrobial therapy can be
determined. Verigene® is an RDT that identifies the genus, species, and select beta-lactamase
resistance determinants for select pathogens within 2-3 hours.2, 4 This RDT allows providers and
antimicrobial stewardship teams to make timely decisions to optimize antibiotic therapy and
potentially improve patient outcomes.5 If interpreted correctly and used promptly,
implementation of RDTs have demonstrated the ability to decrease: time to effective therapy,
cost, length of stay, and mortality.6
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Antimicrobial resistance is a global issue that is threatening our ability to adequately treat
common infectious diseases. Resistance occurs when microorganisms adapt and develop
resistance mechanisms in the presence of antimicrobial drugs. As antibiotic resistance becomes
more and more prevalent, limiting exposure to broad-spectrum antibiotic therapy is of paramount
importance. Rapid diagnostic tests provide more timely information to providers, which if
utilized appropriately, can result in the patient receiving appropriate antibiotic therapy in a shorter
time and further limits unnecessary antibiotic exposure.6, 7 The incidence of multidrug-resistant
(MDR) organisms causing bloodstream infections is increasing.8 A recent review cited that RDT
in combination with antimicrobial stewardship intervention can produce positive outcomes in
regards to patient care, overall health care costs, and antimicrobial stewardship.6
Community Health Network (CHNw) utilizes Verigene® to identify blood cultures and
guide antimicrobial therapy. Verigene® testing is automatically performed on the first
monomicrobial, aerobic blood culture of a particular patient within CHNw. CHNw evaluated the
use of Verigene® in 2017-2018. In this previous evaluation, it was found that 71% of Verigene®
use was appropriate. It was further discovered that an infectious disease consult improved the use
of Verigene® while a blood culture with a gram-negative organism limited its use. This
information led CHNw to embark upon a multi-faceted initiative to further improve the use of
Verigene® as well as reduce the use of anti-pseudomonal beta-lactams across CHNw.
Methods
This was a three-part, retrospective chart review to determine the microbiological
accuracy of Verigene® within CHNw and evaluate the use of Verigene® organism identification
regarding antimicrobial de-escalation of Escherichia coli bacteremia. This data was then used to
compare utilization across CHNw sites based on those who received provider and pharmacist
education versus pharmacist education alone. CHNw consists of 5 primary hospitals (Community
Hospital: East (CHE), North (CHN), South (CHS), Heart and Vascular (CHVH), and Howard
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Regional (CHRH) in the greater Indianapolis, IN area. Each of the 5 hospitals is its own distinct
entity, with a diverse patient population.
The study population consisted of patients from CHE, CHN, CHS, CHVH and CHRH.
CHRH was not included in Aim 3 due to inability to control the type and level of provider
education provided at this site. A patient list was generated from a third-party decision support
program (Vigilanz®) that included patients with both a positive Verigene® result as well as
phenotypic susceptibilities. The list was limited to only the organisms of interest as defined by
the inclusion criteria for each aim. Exclusion criteria for all 3 aims were patients with
polymicrobial bacteremia or on antimicrobials with known culture and susceptibilities at the time
of admission, hospice or palliative care patients, patients <18 years or >89 years old, pregnant,
incarcerated, and behavioral care patients.
Aim 1
The initial aim of this study was to determine the accuracy of the Verigene® test by
comparing its results to the identified organism’s phenotypic susceptibility pattern and
determining the sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) of Verigene® organism identification and presence/absence of resistance genes
detected by Verigene® for antimicrobial susceptibility compared to target antimicrobials.
This aim was a retrospective chart review evaluating patients with positive blood cultures
for Staphylococcus aureus, Enterococcus spp., Escherichia coli, and Klebsiella pneumoniae from
July 1, 2015 to December 31, 2018. Data collection consisted of the Verigene® organisms and
any resistance targets detected and the phenotypic susceptibility results for this organism.
Regarding Staphylococcus aureus, we compared the presence/absence of the MecA gene and the
phenotypic susceptibility to oxacillin. In Enterococcus spp, we compared the presence/absence
of the VanA or VanB gene and the phenotypic susceptibility to vancomycin. In reference to
Escherichia coli and Klebsiella pneumoniae, we compared the presence/absence of CTX-M and
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KPC and the phenotypic susceptibility to ceftriaxone and meropenem and/or ertapenem,
respectively.
Inclusion criteria: Patients 18-89 years of age who had positive, monomicrobic blood
cultures between July 1, 2015-December 31, 2018. Only the first blood culture per
patient per visit was included. The blood culture had to contain both a Verigene® result
and phenotypic antimicrobial susceptibilities. Only cultures with the following target
organisms were included: Staphylococcus aureus, Enterococcus spp., Escherichia coli,
and Klebsiella pneumoniae.
Aim 2
The second aim of this project was to re-evaluate the utilization of Verigene® results in
regard to antimicrobial de-escalation of Escherichia coli bacteremia within CHNw. Secondary
objectives were to compare all cause hospital mortality, 30-day readmission, hospital length of
stay (LOS), and duration of inpatient antibiotics.
This was a retrospective comparative chart review evaluating Verigene® use within
CHNw. Data for this aim was collected through EPIC, the electronic medical record utilized in
CHNw. Demographics, comorbidities, Charlson comorbidity index, antimicrobial allergies,
antimicrobial ordering provider service, presence of an infectious disease consult, Verigene®
identification results, phenotypic susceptibilities, time of de-escalation, 30-day infection related
readmission, and all-cause mortality during hospitalization were collected. Categories of deescalation were defined as either Verigene® utilized (de-escalation of antimicrobial therapy prior
to susceptibilities) or Verigene® not utilized (de-escalation of antimicrobial therapy after
susceptibilities resulted).
Inclusion criteria: Patients 18-89 years of age who were admitted to any CHNw site with
a positive, monomicrobic blood culture for Escherichia coli and initiated on antibiotic
therapy between July 1, 2018-December 31, 2018.
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Aim 3
The final aim was a retrospective comparative chart review using data from the posteducation cohort included in Aim 2 compared to previous data to determine if the education
initiative improved the use of Verigene®. Educational efforts on Verigene® and its
interpretation were provided to key prescribers at CHE, CHN and CHVH, as well as clinical
pharmacists at these sites. Educational efforts at CHS only consisted of pharmacists due to
inability to get provider education scheduled. We compared Verigene® use at CHE, CHN, and
CHVH with CHS. Thus, this aim also evaluated the impact of provider and pharmacist education
compared to pharmacist education alone.
Inclusion criteria: Patients 18-89 years of age who were admitted to any CHNw site with
a positive, monomicrobic blood culture for Escherichia coli and initiated on antibiotic
therapy between July 1, 2018-December 31, 2018.
Statistical Analysis
Descriptive statistics were utilized for baseline characteristics and the primary and
secondary outcomes in the post education group. Statistical analyses between pre- and posteducational groups were compared using the Pearson chi-square test or the Fisher exact test for
dichotomous variables and a student's t-test for continuous variables. A P value of 0.05 was
considered statistically significant. All study data were collected and managed using Excel.
Statistical analysis was completed using Statistical Package for the Social Sciences software,
version 23.0 (IBM Corp., Armonk, NY).
Results
Aim 1
Positive monomicrobic blood cultures for Staphylococcus aureus, Enterococcus spp.,
Escherichia coli, and Klebsiella pneumoniae were obtained from 2,052 positive blood cultures.
Of the 2,052 isolates, 637 (31.0%) were analyzed for the target antimicrobial, oxacillin, 22 (1.1%)
for vancomycin, 739 (36.0%) for ceftriaxone, and 654 (31.9%) for meropenem. Resistance
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determinants were seen in 386 (18.8%) isolates consisting of 101 CTX-M, 8 KPC, 255 MecA,
and 22 VanA or VanB. Table 1 describes the rates of resistance to target antimicrobials,
frequency of Verigene® identification of resistance markers, sensitivity, specificity, PPV, and
NPV. Ceftriaxone resistance was present in 101 (13.7%) of E. coli and K. pneumoniae isolates,
excluding those with KPC genes, and 81 (80.2%) of these were identified with the CTX-M
resistance marker by Verigene®; therefore, the NPV was 97.0%. Denoting that 97% of E. coli
isolates were susceptible to ceftriaxone in the absence of the CTX-M gene by Verigene®.
Meropenem resistance was present in 8 (1.2%) of gram-negative isolates and 3 (37.5%) of those
were identified with the KPC resistance marker by Verigene®; therefore, the NPV was 99.2%.
Ertapenem results were inconsistent; therefore, only meropenem susceptibility was used for KPC
markers. Oxacillin resistance was present in 255 (40.0%) of S. aureus isolates and 254 (99.6%)
of those were identified with the MecA resistance marker by Verigene®; therefore, the NPV was
99.7%. Vancomycin resistance was present in 22 (100%) of Enterococcus spp. isolates and all
were identified with the VanA or VanB resistance markers by Verigene®. The NPV was unable
to be calculated because all resistance markers were identified correctly.
Table 1: Verigene® Results by Target Drug
Target Drug

N

Ceftriaxone
Meropenem
Oxacillin
Vancomycin

739
654
637
22

Resistance
Marker
CTX-M
KPC
MecA
VanA/VanB

N (%)
Resistant
101 (13.7)
8 (1.2)
255 (40.0)
22 (100)

N Identified
by Verigene
81
3
254
22

Sensitivity
(%)
80.2
37.5
99.6
100

Specificity
(%)
99.8
100
100
N/A

PPV
(%)
98.8
100
100
100

NPV
(%)
97.0
99.2
99.7
N/A

NPV = negative predictive value; PPV = positive predictive value

Aim 2
From July 1, 2018 to December 31, 2018, 88 patients were admitted to CHNw with a
positive, monomicrobic blood culture for Escherichia coli and initiated on antibiotic therapy.
Three patients were excluded from analysis due to hospice care. Of the remaining 85 patients, 57
(67.1%) were female and 28 (32.9%) were male. Verigene® was utilized to de-escalate
antimicrobials appropriately (prior to phenotypic susceptibilities) in 29 of 85 patients (34.1%)
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with Escherichia coli bacteremia. There was no statistically significant difference in all-cause
mortality between the Verigene® utilized group and Verigene® not utilized group (5 of 29
(17.2%) vs. 7 of 56 (12.5%), p = 0.533). The difference between readmission within 30 days for
an infectious disease related cause was not statistically significant (Table 2). Additionally, the
mean duration of inpatient antibiotics and length of stay (LOS) did not vary significantly between
groups (Table 2). The duration of antibiotics was measured in days of therapy. If patients
received more than one antibiotic, each day of therapy of each drug was counted separately and
added to the total; therefore, mean duration of antibiotics accounts for more days than LOS.
Table 2: Mean Duration of Antibiotics, Length of Stay, and 30-Day Readmission
Secondary Objective

Verigene® Utilized
mean (days)
SD

Verigene® Not Utilized
mean (days)
SD

p value

Duration of Inpatient Antibiotics

5.69

± 2.055

6.25

± 2.881

0.305

LOS

4.97

± 2.179

3.933

± 3.933

0.290

30-Day Readmission

2 patients

7.1%

3 patients

5.4%

1.000

SD = Standard Deviation

Aim 3
Results pending.
Discussion
For all target antibiotics except meropenem, susceptibility was largely predicted by the
presence/absence of the resistance determinants identified by Verigene®. In the case of
meropenem, the sensitivity of KPC gene alone was not high enough to predict resistance. This
suggests that meropenem resistance was mediated by another mechanism(s). It is well known
that meropenem resistance can occur with a combination of an altered target site mutation and an
efflux pump, without the presence of a beta-lactamase enzyme.9 Although there was a small
sample of Enterococcus spp. isolates, it is encouraging that Verigene® was able to identify the
resistance marker in all 22 samples. In the case of MecA and CTX resistance, the probability of
resistance was 40% and 13.7% respectively; however, the NPV values were 99.7% and 97%.
This should give providers the reassurance that only up to 3% of isolates will be resistant if the
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test is negative. By assessing the accuracy of Verigene® within CHNw, providers may have an
increased confidence in the utilization of this test which could help limit the use of broadspectrum antimicrobials. To further optimize therapy and improve providers’ comfort with
Verigene® utilization, an antibiogram can be developed to display percentages of antimicrobial
susceptibility of target organisms to key antimicrobial agents based on the presence or absence of
resistance markers. Limitations of this analysis include small sample size of certain isolates and
lack of generalizability based on one institution. This information should be analyzed frequently
as mechanisms of resistance can change over time in any given geographic location. This study
is comparable to published studies analyzing the performance of Verigene®. Bork et al10
evaluated 137 isolates of varying gram-negative organisms, including K. pneumoniae (n = 36)
and E. coli (n = 35). Of the resistant organisms, Verigene® detected 1 of 3 CTX-M genes for E.
coli and 4 of 5 CTX-M genes for K. pneumoniae. Pogue et al5 analyzed 1,046 gram-negative
blood cultures at two institutions, including 489 E. coli isolates and 197 K. pneumoniae isolates.
Regarding CTX-M and KPC resistance genes of these two organisms, NPV ranged from 93 to
100%.
Upon reviewing the utilization of Verigene®, a majority (65.9%) of patients’
antimicrobials were not de-escalated until phenotypic susceptibilities resulted. Additionally, an
infectious disease consult did not significantly improve the use of Verigene®, which differed
from our pre-educational cohort. While the results of this cohort were not directly compared to
historical data of the pre-educational cohort at the time of this writing, the initial educational
effort did not seem to improve the utility of the Verigene® test. The lack of significant
differences in Verigene® use seen in Aim 2 of this study, which was also reported in the preeducational cohort, suggests that these educational efforts were not effective or did not reach
enough providers to improve uptake of these results; therefore, more robust education or
additional methods/resources are needed to improve the utility of Verigene® within these
hospitals. Aim 3 analysis is pending; however, it may provide insight as to whether provider
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education made any difference in Verigene® use in the current cohort and whether education is a
reliable method for implementing change at these hospital sites.
Conclusion
As rapid diagnostic testing becomes more widely used within health institutions, it is
important that future studies continue to analyze the accuracy and clinical utility of testing results.
This study helps to highlight the utility of Verigene® within CHNw. Based on these results,
providers at CHNw should feel comfortable de-escalating antimicrobial therapy when Verigene®
does not detect any resistance markers. As the use of Verigene® continues to grow, additional
organisms can be analyzed to establish further credibility.
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